Study Group: Prescribers of Combivir : HIV Specialists (US)
Council Members in this Study Group: 33
This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.
Contact Gerson Lehrman Group to survey or consult with members of this Study Group
Leading institutions connect with members of this Study Group through GLG
Leading Experts in this Study Group
- Steven Fine
Physician
UNIVERSITY OF ROCHESTER MEDICAL CENTER
Steven Fine, MD, PhD, is an HIV and Infectious Disease specialist, an Assistant Professor in the Infectious Disease Unit at the University of Rochester Medical Center, and Staff Physician at Community Health Network. His clinical expertise is all aspects...
- George Beatty
Associate Clinical Professor of Medicine
UNIVERSITY OF CALIFORNIA, SAN FRANCISCOGeorge Beatty, MD, MPH, is Associate Clinical Professor of Medicine at the University of California San Francisco (UCSF), and has been on the faculty since 1998. He served as Director of the UCSF's HIV Clinical Trials Unit at San Francisco General Hospital...
GLG NewsSM Analyses by this Study Group's Leading Experts(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
Simple potent and safe. This HIV combination will be hard to beat.
August 4, 2006
Analysis by: Steven Fine, Physician,New AIDS Pill Simplifies Treatment | www.therapeuticsdaily.com
A three drug "cocktail" for treating HIV all in one pill once a day.
The individual components used together but as individual pills have already proven to be among the most potent and safest regimens for patients first starting HIV treatment.
Trials of this combination have not suggested any increase in resistance compared with other combinations.
Members in this Study Group include these company types:
- Academic Medical Center/Hospital or Clinic
- Office Based Private Practice or Clinic
- Non-Academic Community Hospital or Clinic
- Private/For-Profit Healthcare Research Entity
- Government/Military Hospital or Clinic
- Other Freestanding Healthcare Facility
- Consultancy, Healthcare-Focused
Members in this Study Group often have these job titles:
- Physician - Attending Physician
- Physician - Director
- Physician - Division Head
- Principal
- Owner
- Director
- Medical Director
- Physician - Other Administration
- Physician - Fellow
Related Study Groups
| Study Group Name | No. Members |
|---|---|
| HIV Specialists (US) | 367 |
| Fuzeon Prescribers for HIV (US) | 43 |
| Infectious Diseases Physicians (US) | 885 |
| Viread Prescribers for HIV (US) | 29 |
| Cubicin Prescribers (US) | 180 |
| Maraviroc Experts | 41 |
| Emtriva Prescribers for HIV (US) | 19 |
| Physicians who Treat HCV (US) | 111 |
GLG Live Meetings with this Study Group's Leading Experts (?)
February 23, 2007 | New York
GLGi: Emerging Therapies for HIV Grand RoundsGLG Webcasts & Teleconferences
Leading Experts in Prescribers of Combivir : HIV Specialists (US) have not participated in any GLG webcasts.